Protein disulfide isomerase blocks the interaction of LC3II-PHB2 and promotes mTOR signaling to regulate autophagy and radio/chemo-sensitivity

Ruru Wang1,2, Yajing Shang1,3, Bin Chen1,2, Feng Xu1,2, Jie Zhang1,2, Zhaoyang Zhang1,2, Xipeng Zhao1,4, Xiangbo Wan1,4 and Guoping Zhao1,5

© The Author(s) 2022

Protein disulfide isomerase (PDI) is an endoplasmic reticulum (ER) enzyme that mediates the formation of disulfide bonds, and is also a therapeutic target for cancer treatment. Our previous studies found that PDI mediates apoptotic signaling by inducing mitochondrial dysfunction. Considering that mitochondrial dysfunction is a major contributor to autophagy, how PDI regulates autophagy remains unclear. Here, we provide evidence that high expression of PDI in colorectal cancer tumors significantly increases the risk of metastasis and poor prognosis of cancer patients. PDI inhibits radio/chemo-induced cell death by regulating autophagy signaling. Mechanistically, the combination of PDI and GRP78 was enhanced after ER stress, which inhibits the degradation of AKT by GRP78, and eventually activates the mTOR pathway to inhibit autophagy initiation. In parallel, PDI can directly interact with the mitophagy receptor PHB2 in mitochondrial, then competitively blocks the binding of LC3II and PHB2 and inhibits the mitophagy signaling. Collectively, our results identify that PDI can reduce radio/chemo-sensitivity by regulating autophagy, which could be served as a potential target for radio/chemo-therapy.

Cell Death and Disease (2022)13:851; https://doi.org/10.1038/s41419-022-05302-w

INTRODUCTION

Colorectal cancer (CRC) has been identified as the third largest cancer in the world, and the global incidence rate and mortality are still rising [1]. Currently, chemo-therapy or radio-therapy combined with surgery is used as the backbone for treating metastatic CRC, which, unfortunately, shows limited efficacy [2, 3]. Autophagy, as type II programmed cell death, is a complex process of intracellular degradation of senescent or malfunctioning organelles. Recently, autophagy inhibitors or inducers have overcome multidrug or radio-resistance of cancer cells, suggesting that autophagy is a new target for cancer therapy [4–6]. Up to now, the dual role of autophagy both in cancer progression and inhibition remains controversial.

Protein disulfide isomerase (PDI), also known as prolyl 4-hydroxylase beta, is a highly abundant multifunctional enzyme that belongs to the PDI family, which is classically characterized by endoplasmic reticulum (ER) localization and redox activity [7–9]. PDI family proteins, such as AGR2, PDI, PDIA3, PDIA4, and PDIA6 are reportedly upregulated in cancers [10–16], which are correlated with cancer progression and metastatic disease in pancreatic [17], kidney renal clear cell carcinoma (KIRC) [11], ovarian cancers [18], glioblastoma [19–21] and lung adenocarcinoma [22]. Increasing evidence suggests that PDI supports the survival and progression of several cancers by regulating endoplasmic reticulum stress (ERS), apoptosis, DNA repair, and autophagy [7]. For example, PDI knockout reduces DNA repair after ionizing radiation (IR) and enhances the killing ability of radiation on GBM cells [23]. Besides, knockdown of PDI can remove survival responses to ERS, thereby promoting melanoma cell death [24]. Inhibition of PDI results in increased autophagy, and prevents the death of dopaminergic neurons [25]. PDI inhibitors have been shown to enhance chemo-sensitivity both in vitro and in vivo [26, 27]. Given the emerging role of PDI in cancer, PDI is generally described as a proto-oncogene and potential cancer biomarker [20, 28]. However, the expression of PDI is also correlated with positive clinical outcomes. For example, breast patients with elevated levels of autoantibodies against PDI were found to have higher survival [29]. PDI mediates the decrease of H2O2 level in the ER of cervical cancer cells and inhibits cell migration, invasion, and tumor growth [30]. In addition, overexpression of PDI family protein ERp29 significantly inhibits proliferation and tumorigenesis by regulating ERS signals and mesenchymal-epithelial transition in breast cancer cells [31].

One explanation for the disparate prognostic correlation between PDI family proteins and patient outcomes may involve...
the differences in PDI cellular localization, and depends on whether the cellular concentration of the PDIs can reach a certain threshold to initiate tumor suppressor function. For example, PDI prevents apoptotic signaling associated with ERS and protein misfolding in various in vivo and in vitro models, however, higher concentrations of purified PDI (0.5–1.5 μM) promote MOMP in vitro [32]. Tiemann et al. found that AGR2 in the extracellular promoted the phosphorylation of RICTOR and inhibited tumor metastasis, whereas intracellular AGR2 antagonized its level and phosphorylation and promoted tumor metastasis. This indicates that the PDI family protein can participate in the regulation of tumor progression through different cell localizations or intracellular concentrations [33]. Another possibility is that PDI plays a double-sided role in autophagy signaling [4, 34]. Studies have reported that PDI may participate in autophagy regulation through GRP78 or ERS to regulate tumor development [7, 35–37]. However, the detailed molecular mechanisms of PDI-mediated autophagy are not completely known.

In this study, we set out to explore the regulatory mechanism of PDI in autophagy and the role of PDI-mediated autophagy in radio/chemo-therapy sensitivity of CRC. Our study demonstrated that PDI regulates autophagy through the AKT-mTOR pathway and binds with PHB2 to inhibit the autophagy pathway. We further extended the mechanistic explanation and found that PDI could inhibit the death of CRC cells by inhibiting the autophagy level, which reduced the sensitivity of radio/chemo-therapy.

RESULTS
PDI is elevated in human colorectal cancer tissues and is associated with a poor prognosis

Our previous study identified genes that were differentially expressed between CRC cells and IR treatment using RNA sequencing analyses [38]. PDI was one of the upregulated genes identified in CRC cells (Supplementary Fig. S1a). To investigate the role of PDI in CRC, we analyzed the transcriptional datasets assembled from clinical samples in the public database GEPIA (http://ggepia.cancer-pku.cn) and discovered that the transcriptional levels of PDI were dramatically increased in various cancers, especially in CRC cancer tissues (Fig. 1A and Supplementary Fig. S1b–d). Further analysis showed that the level of PDI protein in CRC tissues (n = 30) and five tumor cell lines was also higher than that in paired adjacent normal tissues and normal human intestinal epithelial cells (HIEC), respectively (Fig. 1B–D). Consistent with these results, immunohistochemistry staining of CRC showed strongly positive PDI staining in clinical CRC tissues, but weakly positive or negative PDI staining in adjacent normal tissues (Fig. 1E, F). To clarify the clinical relevance of PDI, we tested the potential association between PDI expression and clinic pathological features in 60 CRC patients. As shown in Table 1, the expression of PDI is significantly correlated with the survival status of patients, but not with gender, age, lymph node metastasis, or age. Importantly, univariate cox regression analysis showed that both PDI expression and gender were important predictors of overall survival in patients with CRC (Fig. 1G).

PDI decreases radio/chemo-sensitivity in cancer cells

To further investigate the role of PDI in CRC, PDI knockdown or overexpressed cell lines were established in HCT116, MEF, and A549 cells (Fig. 2A, B and Supplementary Fig. S2a, b). MEF cells used here were immortalized by infection with SV40 large T antigen-expressing lentivirus, which has the characteristics of cancer cells [39]. Then, we used CCK-8 analysis to evaluate the effect of PDI on the viability of cells. The results showed that cell viability was decreased in cells following PDI knockdown, but increased in cells overexpressing PDI compared to the corresponding control groups (Fig. 2C, D and Supplementary Fig. S2c, d). Next, to further validate the oncogenic activity of PDI in radio/chemo-sensitivity, the cells were treated with radio/chemo-therapy. The results indicated that knockdown of PDI significantly increased radiation (IR) or cisplatin (Cis) induced cytotoxic effects in HCT116 cell viability, whereas PDI overexpression showed the opposite effect (Fig. 2E, F). Consistently, flow cytometry analysis with annexin V/PI double staining showed that PDI knockdown increased the apoptotic rate of HCT116 and A549 cells compared to control shRNA after IR/Cis treatment (Fig. 2G, H and Supplementary Fig. S2e). Caspase activity analysis also showed an increased apoptotic rate in PDI knockdown cells, and a decreased apoptotic rate in PDI overexpressing cells after IR treatment (Fig. 2J and Supplementary Fig. S2f–h). Similar results were obtained in a colony formation assay in HCT116 cells (Supplementary Fig. S2i, j). These data indicate that PDI plays a role in promoting cell proliferation as an oncogene, and PDI inhibits IR/Cis-induced apoptotic cell death.

PDI regulates radio/chemo-sensitivity by regulating autophagy

Next, we detected whether autophagy signaling was involved in PDI-mediated radio/chemo-sensitivity. TEM assays and western blot is presented to show that PDI knockdown combined with IR treatment increased the formation of autophagosomes (Fig. 3A–C), enhance light chain 3II (LC3II)/I ratio, and decrease p62 protein level compared with control cells upon radiation in HCT116 cells (Fig. 3D, E and Supplementary Fig. S3a). Increased LC3II/I ratio and decreased p62 protein level were also found in A549 PDI knockdown cells. Moreover, the number of green fluorescent punctas was strongly increased under IR treatment in PDI knockdown HCT116 cells (Fig. 3F, G). Similarly, compared with the control group, knockdown of PDI can also enhance cisplatin-induced autophagy (Fig. 3H, I). However, overexpression of PDI has less effect on radio/chemo-induced autophagy. Those results demonstrate that knockdown PDI can accelerate the process of autophagy during cell treatment with radio/chemo-therapy.

Knockdown PDI promotes chemo/radio-therapy sensitivity

To further investigate the mechanism of PDI participating in autophagy, the autophagy inhibitor chloroquine (CQ) and 3-methyladenine (3-MA) prevent the end-stage or early-stage process of autophagy was used. As shown in Fig. 4A–D and Supplementary Fig. S4a, b, the combination of CQ pretreatment and IR/Cis significantly increased the accumulation of LC3II in PDI knockdown cells, but not in overexpression cells, compared with the IR/Cis alone. Knockdown or overexpressing PDI did not affect autophagy after inhibiting early autophagy by 3-MA pretreatment (Fig. 4E, F and Supplementary Fig. S4c, d). Importantly, both 3-MA and CQ decreased radio/chemo-resistance in PDI knockdown cells but not overexpression cells (Fig. 4G–J and Supplementary Fig. S4e, f). Moreover, the autophagy inducer rapamycin or EBSS combined with IR/Cis treatment can significantly enhance the autophagy level and decrease cell viability in cells (Fig. 4K, L and Supplementary Fig. S4g, h). These results signified that overexpression of PDI increases cell viability by attenuating autophagy signaling, and thus enhances cellular radio/chemo-therapy resistance, and that the function of PDI in radio/chemo-resistance is mainly autophagy-dependent.

As PDI plays an important role in cells depending on its enzyme activity, we also studied whether the enzyme activity of PDI was involved in autophagy signaling. PDI enzyme activity inhibitors bacitracin and securinine were used. We found that bacitracin and securinine failed to affect the autophagy level and cell viability of cells upon radiation. (Supplementary Fig. S4i–l), indicating PDI-induced autophagy was independent of its catalytic activity.
PDI interacts with GRP78, leads to ERS, and activates AKT/mTOR signaling pathway

To investigate the mechanism of PDI participating in autophagy, we conducted an RNA sequencing analysis to identify potential pathways involved in PDI-mediated autophagy signaling. The results indicated that AKT/mTOR pathway mainly participates in PDI-mediated autophagy after radiation treatment (Supplementary Fig. S5a). As shown in Fig. 5A–D, increased levels of GRP78, a well-characterized marker for ERS [40], were observed after IR/Cis treatment. The level of phosphorylated PERK, but not the ER membrane-spanning UPR receptor protein ATF6 was increased upon IR/Cis treatment. PDI knockdown promoted IR/Cis-induced ERS and decreased the levels of phosphorylated AKT and mTOR but not their total protein levels, whereas PDI overexpression promoted AKT and mTOR phosphorylation after IR/Cis in HCT, A549, and MEF cells (Fig. 5E, F and Supplementary Fig. S5b). Knockdown of PDI also increased the protein expression level of ULK1 after IR/Cis treatment (Supplementary Fig. S5c). These results indicated that PDI-mediated autophagy induced by IR/Cis in an AKT-mTOR-ULK1 signaling-dependent manner. To further explore the mechanism, we performed an online data analysis (https://string-db.org/) and observed that GRP78 may function as

Fig. 1 PDI is elevated in human colorectal cancer tissues and is associated with poor prognosis. A TCGA database was used to analyze the expression of PDI mRNA in CRC tissue (T) and normal tissue (N). B Expression of PDI protein in normal intestinal epithelial and tumor cells. C, D The level of PDI protein in 30 pairs of colorectal cancer tissues (T) and paired adjacent normal tissues (N) was analyzed by western blot (C). Quantification of protein levels (D) was normalized to those of β-actin. E, F Represent immunohistochemically staining (E) and IHC score (F) of PDI expression in CRC and adjacent normal tissues. Original magnification, ×40 (outside) or ×400 (inset). Scale bar = 50 μm. G Forest plots for univariate analysis of the correlation between clinicopathological features of colon cancer and mortality. Data are presented as the mean ± SD (***P < 0.001 by Student’s tests).
Table 1. Demographic and clinicopathological parameters of patients with hepatocellular carcinoma (data from 30 clinical patients).

| Characteristic          | PDI expression | χ²  | P value |
|-------------------------|----------------|-----|---------|
|                         | High (n = 17)  |     |         |
|                         | Low (n = 13)   |     |         |
| Age (years)             |                |     |         |
| <60                     | 9              | 6   |         |
| ≥60                     | 8              | 7   | 0.24    | 0.624   |
| TNM stage               |                |     |         |
| I                       | 4              | 5   |         |
| II                      | 3              | 4   |         |
| III                     | 4              | 3   |         |
| IV                      | 6              | 1   | 3.497   | 0.321   |
| Gender                  |                |     |         |
| Male                    | 11             | 5   |         |
| Female                  | 6              | 8   | 2.039   | 0.153   |
| Lymph node metastasis   |                |     |         |
| Positive                | 3              | 0   |         |
| Negative                | 14             | 13  | 2.549   | 0.11    |
| Survival status         |                |     |         |
| Death                   | 5              | 0   |         |
| Survival                | 12             | 13  | 19.714  | 0.032   |

DICUSSION
Recent studies have demonstrated that the adaptive autophagy system can regulate radio/chemo-sensitivity of various cancers [5, 42, 43]. However, the potential role of the PDI in regulating autophagy in CRC radio/chemo-resistance is poorly understood. Through a combination of bioinformatics, biological, and clinical studies, we have demonstrated that autophagy-related pathways are enriched and activated in CRC cells and the overexpression of PDI promotes CRC radio/chemo-resistance. Mechanistic studies showed that under radio/chemo-therapy conditions, PDI interacts with GRP78 to inhibit the degradation of Akt, and eventually activates the mTOR pathway and inhibits autophagy initiation. In parallel, radio/chemo-therapy mediates the transfer of PDI from the ER to mitochondria, and translocated PDI competes with LC3 to bind PHB2 on mitochondria to inhibit autophagy (Fig. 8). This study proposes that promoting autophagy in specific cells, such as cancer cells with low levels of PDI, can cause excessive autophagy, which will increase the sensitivity of radio/chemo-therapy.

Since high expression of PDI was detected in many cancers, including glioblastoma, non-small cell lung cancer, pancreas, multiple myeloma, and various radio/chemo-resistance cell lines, PDI is of particular interest concerning cancer [23, 44]. PDI might be one potential novel KiRRC diagnostic and prognostic biomarker at both the mRNA and protein levels [11]. Here, using new generation sequencing methods together with the detection of clinical samples, we also found that PDI is a prognostic biomarker for CRC (Fig. 1) [45]. To our knowledge, previous studies have highlighted the oncogenic role of the PDI family in cancer cells and have established an important role in the quality control of the autophagy system [14, 18]. Some researchers have...
conjectured that the capacity of PDI to regulate protein degradation pathways and autophagy systems may contribute to the radio/chemo-resistance phenotype [15, 19, 20]. In this study, we found for the first time that the expression level of PDI was significantly correlated with the clinical survival status of patients with colon cancer. There is a positive correlation between cancer grade and PDI expression in colon cancer. PDI promotes the malignant development of tumors.

Our findings displayed a novel mechanism that PDI resulted in the radio/chemo-resistance by reducing the autophagy level.

Fig. 2 PDI decreases radio/chemo-sensitivity in cancer cells. A, B Immunoblot analysis of PDI protein in PDI knockdown or overexpression HCT116 (A), and semi-quantitative statistics using image software (B). C, D CCK-8 assay analysis of the impact of knockdown (C) or overexpression of PDI (D) on the viability of HCT116 cells. E, F CCK-8 assay analysis of HCT116 cells after γ-ray or cisplatin for 24 h. G, H The apoptotic cells were assessed by annexin V-FITC/PI staining after being treated with γ-ray (4 Gy) irradiation for 24 h (G), flowjo software performs data statistics. I, J Caspase3/7 kit was used to detect the effect of knockdown or overexpression of PDI combined with γ-ray (4 Gy) or cisplatin (20 μM) for 24 h on the apoptosis of HCT116 cells. Data of at least three independent experiments performed in duplicate are presented as mean ± SEM. shNC shRNA control, shPDI#1/2/3 shRNA-1/2/3 targeting PDI, Vector control plasmid, OE-PDI PDI overexpression plasmid. *P < 0.01, **P < 0.01, ***P < 0.001 compared with shNC. ##P < 0.01, ###P < 0.001 compared with control vector plasmid transfected cells.
Therefore, the enhancement of autophagy may have a considerable impact on the treatment of radio/chemo-resistance tumors. Consistent with previous results [36], we confirmed that IR/CIS treatment activated the ERS pathway, which enhanced the binding of PDI with GRP78, and then inhibited the degradation of Akt, and finally reduced autophagy signaling [46]. GRP78 facilitates the translocation of mitochondrial stabilization proteins to mitochondria to promote mitochondrial stability and regulate autophagy after ERS [46]. ER-localized GRP78 was also required for multiple protein translocation, and this information indicates that the translocation dependence on GRP78 has an important effect on regulating autophagy [47]. In our study, PDI was widely distributed on the ER membrane and transferred to the mitochondria after radio/chemo-therapy (Fig. 6). Online data analysis and Co-IP assay all observed that GRP78 may function as a PDI substrate protein, and the interaction of PDI and GRP78 was

Fig. 3  PDI regulates radio/chemo-sensitivity by regulating autophagy.  A–C HCT116 cells were treated with γ-ray (4 Gy) irradiation for 24 h and were then subjected to transmission electron microscopy assay. Scale bar = 2 μm (left) or scale bar = 1 μm (right). Arrows indicate autophagosomes or autolysosomes (A). The average number of autophagosomes (B) or autolysosomes (C) per cell was quantified. D, E Western blot showed levels of autophagy-related proteins in PDI knockdown or overexpression cells after being treated with IR for 24 h and the results were quantified. F, G HCT116 cells or PDI knockdown cells transiently transfected with mCherry-GFP-LC3B plasmid and after 24 h were treated with γ-ray (4 Gy) irradiation for 24 h. The distribution of LC3II was visualized by confocal microscopy (up) and the average number of GFP-LC3 dots per cell was quantified (down). Scale bar = 25 μm. H, I Western blot showed levels of autophagy-related proteins in HCT116 cells after being treated with cisplatin (20 μM) for 24 h. Data of at least three independent experiments performed in duplicate are presented as mean ± SEM. *P < 0.01, **P < 0.01, ***P < 0.001 compared with shNC. #P < 0.05, ##P < 0.01, ###P < 0.001 compared with control vector plasmid transfected cells.
notably promoted by IR/Cis stimulation (Supplementary Fig. S5d and Fig. 5). We suspected that the translocation of PDI to mitochondria may also be dependent on GRP78. HCT116 is a K-Ras-positive cell line and some reports have found that mutations in RAS are associated with autophagy initiation through RAS-MEK-ERK and PI3K-AK-mTOR signaling pathways [48]. RAS-MEK-ERK pathway plays a central role in tumorigenesis and is a target of anticancer therapy [49]. Based on our sequencing data, although the ERK pathway was activated in HCT116 cells after radiation, AKT-mTOR pathway had the highest enrichment score among KEGG pathways, which implied that it played a dominant role in regulating PDI-mediated autophagy (Supplementary Fig. S5a).

PDI was originally identified as a disulfide isomerase containing two thioredoxin domains that catalyze the formation, breakage, and rearrangement of disulfide bonds, thus radio/chemo-resistance in PDI-overexpression cancer cells was considered to correlate with its enzyme activity [50]. However, we found that inhibition of PDI enzymatic activity had no significant effect on autophagy, suggesting that PDI-regulated autophagy is independent of its enzymatic activity. Besides, the inhibition of the ERS pathway does not block autophagy signaling completely, hence, other pathways are involved in PDI-mediated autophagy. Here, immunofluorescence study indeed found that after IR/Cis treatment, there was a co-localization between PDI and PHB2. The interaction between PDI and PHB2 was further confirmed in vitro. PHB2 is a newly discovered mitochondrial autophagy receptor, which can bind to autophagy membrane-associated protein LC3 through the LC3 interaction region domain to directly mediate autophagy.

**Fig. 4** Knockdown PDI to promote chemo/radio-therapy sensitivity. A–D HCT116 cells were pretreated with or without 10 µM CQ (A) or 5 mM 3-MA (C) for 2 h, and then radiated with 4 Gy γ-ray for 24 h. LC3II accumulation was measured using WB. E, F CCK-8 assay analysis of the impact of cell viability pretreated with or without CQ (E) or 3-MA (F) for 2 h. G–J HCT116 cells were irradiated with 4 Gy γ-ray for 24 h, after that treated with 10 µM EBSS (G) or rapamycin (H) that induced autophagy. LC3II accumulation was measured using WB. K–L CCK-8 assay analysis of the impact of cell viability treated with EBSS (K) or rapamycin (L). Data of three independent experiments are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared with control.
autophagy [51]. We also found that the total protein level of PHB2 did not change in PDI knockdown or overexpression cells, but knockdown PDI increased the expression level of PHB2 in purified mitochondria after IR/Cis treatment. Previous studies have shown that proteasome-dependent OMM rupture is required for the interaction between PHB2 and LC3II [41]. We speculated that the depolarization of MMP caused by PDI knockdown may induce the recruitment of the PHB2 to mitochondrial. In the following experiments, it was found that in the presence of activation signaling, translocated PDI interacts with PHB2 through its thioredoxin-6 domain subunit, which competitively blocks the binding of LC3II with PHB2 and subsequently inhibits the mitophagic signaling and further promote cell death induced by radio/chemo-therapy.

In conclusion, the current study discovers a new molecular mechanism of PDI in CRC by regulating ER oxidative stress and the autophagy signaling pathway. Specifically, on the one hand, PDI reduced autophagy through the ERS pathway, and on the other hand, PDI interacts with GRP78, leads to ERS, and activates AKT/mTOR signaling pathway.
**Fig. 6 PDI prevents autophagy by regulating mitophagy.**

A–D The interaction between PDI and PHB2 was detected by immunoprecipitation after the treatment with γ-ray (4 Gy) irradiation (A, B) or 20 µM cisplatin (C, D) for 24 h in HCT116 and MEF cells. E, F Immunofluorescence microscope analysis of co-localization of PDI (red) and PHB2 (green) in PDI knockdown or PDI overexpression HCT116 cells after 24 h of treatment with IR (4 Gy) (E) or cisplatin (20 µM) (F). Blue DAPI staining was used to stain the cell nucleus. Scale bar = 25 µm.

G The interaction between PDI and PHB2 was detected by Flag-pull down in vitro. Purified Flag-PHB2 or Myc-PDI immobilized on the beads was incubated with purified Myc-PDI or Flag-PHB2. Input and bead-bound proteins were analyzed by immunoblotting with anti-PDI or anti-PHB2 antibodies.

H The changes in the MMP of HCT116 cells before and after γ-ray (4 Gy) irradiation for 24 h were detected by the JC-1 probe.

I Statistical map of MMP.

J The expression of ROS in HCT116 cells after γ-ray (4 Gy) irradiation for 24 h. K, L Expression of mitophagy-related proteins in mitochondria treated with γ-ray (4 Gy) irradiation (K) after 24 h in HCT116 cells or treated with cisplatin (20 µM) after 24 h in MEF cells (L). Data were pooled from three independent experiments and the results are represented as mean ± SD; *P < 0.05, **P < 0.01, ***P < 0.001.
hand, PDI competitive binding to the mitochondrial autophagy receptor PHB2 inhibits autophagy through its thioredoxin-6 domain. Altogether, our studies highlight the essential roles of PDI-dependent autophagy in radio/chemo-resistance. These new molecular insights provide an important contribution to better understand the mechanism of PDI enhancing tumor cell resistance to radio/chemo-therapy.

MATERIALS AND METHODS

Patients and tissue specimens
A total of 60 cases of matched CRC and para tumor tissue samples were collected from patients who were diagnosed with CRC from 2016 to 2021 at The Sixth Affiliated Hospital, Sun Yat-sen University (Guangdong, China). Patients were classified according to TNM stags (American Joint Committee on Cancer, 8th edition), and well documented with complete follow-ups for 5 years or until death. According to the established plan approved by the ethics committee of the Sixth Affiliated Hospital of Sun Yat-sen University, samples were obtained with informed consent. The detailed clinic pathological characteristics are given in Table 1.

Cell cultures, irradiation, and regents
The human cell lines HCT116, HEK293T, A549, HIEC, and MEF cells were kindly provided by Dr Chi Li (University of Louisville, Kentucky, USA). The human cell line LOVO was obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cell lines of MEF were obtained from Craig Thompson (MSKCC, NY, USA). All cells were maintained in...
purchased from Beyotime (Shanghai, China) as follows: anti-FLAG (AF0036), anti-HIS (AF5060), and anti-MYC (AF0033).

Stable cell line construction

pLKO.1-puro lentiviral vectors expressing shRNAs targeting PDI were purchased from Sigma-Aldrich. All vectors contain a puromycin antibiotic resistance gene for selecting transduced cells. Lentivirus production and transduction were performed as described previously [53]. Briefly, transduced HCT116, A549, and MEF cell populations were selected with 1.5 μg/ml puromycin for 7 days and knockdown efficiency was identified by western blotting. shRNA sequences used in the study are listed in the following:

- PDI-shRNA-1-F: CCGG CGAC AGGA CGGT CATT GATT ACTC GAGT
- PDI-shRNA-1-R: AATT CAAA AAGT GTGG TCAC
- PDI-shRNA-2-F: CCGG TGAC CAGC TACA AGG C TCTG GAGA TTGCC
- PDI-shRNA-2-R: AATT CAAA AAGT GTGG TCAC
- PDI-shRNA-3-F: CCGG GTGT GGTG ACTG CAAAG CAGT TCTG GAGA TTG
- PDI-shRNA-3-R: AATT CAAA AAGT GTGG

Ad-mRFP-GFP-LC3B transfection

Ad-mRFP-GFP-LC3B vectors were transfected according to the manufacturer’s instructions (Beyotime, Shanghai, China), and transfected cells were cultured for 48 h. After transfection with adenoviral vectors and treatments as described in figure legends, cells were washed with PBS and fixed with ice-cold 100% methanol for 30 min. After washing, coverslips were mounted on glass slides and examined using a fluorescence microscope (Olympus, Tokyo, Japan).

Immunohistochemistry tissues

Tissues fixed with 4% paraformaldehyde in PBS for 60 min. After permeabilization, sections of tissue were stained using PDI antibodies. Images were acquired using an optical microscope or a laser scanning confocal microscope (Leica, Tokyo, Japan) and Leica TCS SP8 (Leica, Tokyo, Japan). PDI immunostaining was evaluated using a semi-quantitative scoring system.

Transmission electron imaging

Cells cultured on a 12-well incubator slide were fixed in 4% paraformaldehyde for 30 min, treated with 0.1% Triton X-100 in PBS for 30 min, and incubated with 3% BSA under RT for 2 h at RT. After overnight incubation with primary antibody at 4°C, the cells were washed and incubated with secondary antibody under RT for 2 h. DAPI (Sigma-Aldrich, Missouri, USA) was used to stain the nuclei. Images were visualized by an orthostatic two-photon confocal microscope (Nikon, Tokyo, Japan).

Co-immunoprecipitation and western blot

Extract the cell lysates from the cell lysis buffer and quantify the protein concentration in the lysates using the BCA protein determination kit (Thermo Fisher, CA, USA). Protein samples with 20–60 μg were loaded for IB. For Co-IP samples, equal amounts of protein were incubated with the primary antibody or non-specific immunoglobulin G and protein G-agarose beads (Beyotime, Shanghai, China) at 4°C with rotation overnight after lysis. The beads were collected by centrifugation and washed five times with the RIPA buffer. Immuno-complexes were eluted with 30 μl of SDS sample buffer and heated at 95°C for 10 min. Cell extracts and immunoprecipitates were separated by SDS–PAGE and transferred onto PVDF membranes (Roche, Basel, Switzerland). Membranes were incubated with primary antibodies followed by secondary antibodies and visualized with ECL plus (Amersham Bioscience, London, UK).

HIS pull-down assays

LC3-His, PDI-Myc were cloned into the pGEX-6P-1 vector. The construct was transformed into Escherichia coli Rosetta2 (DE3) cells. The cells were cultured at 37°C until the A600 reached 0.6 and then induced with 0.2 mM isopropyl β-d-thiogalactoside (Takara, Tokyo, Japan) for 16 h at 25°C. The cells were suspended and sonicated. After spinning, the supernatant was incubated with glutathione Sepharose beads (GE Healthcare, Beijing, China) for 12 h. Reduced glutathione (Beyotime, Shanghai, China) was then used to wash the agarose beads and collect the eluent for the indicated experiments. 293T cells were transfected with vector and Flag-PHB2. Cell

Ad-mRFP-GFP-LC3B transfection

Ad-mRFP-GFP-LC3B vectors were transfected according to the manufacturer’s instructions (Beyotime, Shanghai, China), and transfected cells were cultured for 48 h. After transfection with adenoviral vectors and treatments as described in figure legends, cells were washed with PBS and fixed with ice-cold 100% methanol for 30 min. After washing, coverslips were mounted on glass slides and examined using a fluorescence microscope (Olympus, Tokyo, Japan).

Immunohistochemistry tissues

Tissues fixed with 4% paraformaldehyde in PBS for 60 min. After permeabilization, sections of tissue were stained using PDI antibodies. Images were acquired using an optical microscope or a laser scanning confocal microscope (Leica, Tokyo, Japan) and Leica TCS SP8 (Leica, Tokyo, Japan). PDI immunostaining was evaluated using a semi-quantitative scoring system.

Transmission electron imaging

Cells cultured on a 12-well incubator slide were fixed in 4% paraformaldehyde for 30 min, treated with 0.1% Triton X-100 in PBS for 30 min, and incubated with 3% BSA under RT for 2 h at RT. After overnight incubation with primary antibody at 4°C, the cells were washed and incubated with secondary antibody under RT for 2 h. DAPI (Sigma-Aldrich, Missouri, USA) was used to stain the nuclei. Images were visualized by an orthostatic two-photon confocal microscope (Nikon, Tokyo, Japan).

Co-immunoprecipitation and western blot

Extract the cell lysates from the cell lysis buffer and quantify the protein concentration in the lysates using the BCA protein determination kit (Thermo Fisher, CA, USA). Protein samples with 20–60 μg were loaded for IB. For Co-IP samples, equal amounts of protein were incubated with the primary antibody or non-specific immunoglobulin G and protein G-agarose beads (Beyotime, Shanghai, China) at 4°C with rotation overnight after lysis. The beads were collected by centrifugation and washed five times with the RIPA buffer. Immuno-complexes were eluted with 30 μl of SDS sample buffer and heated at 95°C for 10 min. Cell extracts and immunoprecipitates were separated by SDS–PAGE and transferred onto PVDF membranes (Roche, Basel, Switzerland). Membranes were incubated with primary antibodies followed by secondary antibodies and visualized with ECL plus (Amersham Bioscience, London, UK).

HIS pull-down assays

LC3-His, PDI-Myc were cloned into the pGEX-6P-1 vector. The construct was transformed into Escherichia coli Rosetta2 (DE3) cells. The cells were cultured at 37°C until the A600 reached 0.6 and then induced with 0.2 mM isopropyl β-d-thiogalactoside (Takara, Tokyo, Japan) for 16 h at 25°C. The cells were suspended and sonicated. After spinning, the supernatant was incubated with glutathione Sepharose beads (GE Healthcare, Beijing, China) for 12 h. Reduced glutathione (Beyotime, Shanghai, China) was then used to wash the agarose beads and collect the eluent for the indicated experiments. 293T cells were transfected with vector and Flag-PHB2. Cell
lysates were immunoprecipitated with anti-Flag beads (Sigma-Aldrich, Missouri, USA). Supernatants (Flag, Flag-PhB2) were mixed with glutathione agrose beads (Thermo Fisher, CA, USA) for 4 h at 4 °C. The beads were washed three times with the corresponding lysis buffer. Finally, the cell lysates were immunoprecipitated with anti-Flag M2 affinity beads (Sigma-Aldrich, Missouri, USA), and then subjected to SDS/PAGE and western blots with antibodies.

**Cell viability, apoptosis, and colony formation assay**

The HCT116 and MEF cells were seeded at a density of 2 × 10^3 per well in 96-well plates. At indicated time post-irradiation, cell viability was measured using the CCK-8 assay (Solarbio, Beijing, China) according to the manufacturer’s instructions. For cell apoptosis analysis, cells were treated according to the instructions provided with the PI apoptosis detection kit (Solarbio, Beijing, China). Apoptotic ratios were analyzed using FlowJo 10.0 Software, both early apoptotic cells and late apoptotic cells were nominated as apoptotic cells. In the colony formation test, 1 × 10^5 cells were plated in a six-well cell culture plate. After 10 days of growth, the colonies on the plate were fixed with 4% parafomaldehyde, stained with crystal violet, and counted under a × 100 microscope.

**Caspase activity assays**

We seeded 5 × 10^6 PDI overexpressing and knockdown cells and their parental controls in a 96-well plate. Caspase3/7 activity was measured by a Caspase-Glo3/7 Assay (Promega, WI, USA) according to the manufacturer’s protocol.

**Mass spectrometry (MS)**

The cells were centrifuged and collected at 12,900 rpm for 15 min at 4 °C. Proteins in the lysates were immunoprecipitated using anti-PDI or anti-Flag antibodies. Protein A/G PLUS-agarose beads were incubated with proteins for 12 h and washed five times with the lysis buffer. The PDI complexes were eluted from the beads using 0.1 M glycine–HCl. Then, the endogenous PDI complexes were analyzed in linear mode by tandem MS (MS/MS) performed in Shanghai Applied Protein Technology (APTBIO, China). The resulting MS/MS data were processed using the MaxQuant search engine (v.1.5.2.8).

**Cytosol/mitochondria fraction preparation**

Cells were lysed by mechanical braking into a detergent-free buffer (0.25 M sucrose, 10 mM HEPES pH 7.5, 1 mM EDTA) subsequently, according to the manufacturer’s instructions, mitochondria were separated using the cell mitochondrial separation Kit (Beyotime, Shanghai, China).

**Immunofluorescence microscopy**

Cells were fixed and permeabilized with ice-cold 100% methanol for 10 min followed by 30 min in PBS 0.1% Triton X-100 and then washed with PBS. The cells were incubated with primary antibody overnight followed by a washing step. The cells were incubated with the secondary antibody for 1 h at RT. Before mounting in fluorescent mounting medium cells were washed three times with PBS. The image was obtained on Olympus fluorescent 1000 confocal microscope (Olympus, Tokyo, Japan).

**Statistical analysis**

SPSS 17.0 software (IBM, NY, USA) was used for clinical statistical analyses. An unpaired two-tailed Student’s t-test was used to compare the two groups with normally distributed data. Pearson’s χ^2 test was applied to analyze the correlation between the expression of PDI and clinico-pathological features. The statistical significance of differences between groups was assessed using the GraphPad Prism5 software (San Diego, CA, USA). All data are presented as the mean ± standard error of the mean unless otherwise specified. Student’s t-test or one-way ANOVA was used to determine the significance of all quantitative experiments. All experiments were repeated at least three times. P < 0.05 was considered significant, statistical significance was defined as “*P < 0.05, **P < 0.01, ***P < 0.001, ##P < 0.05, ###P < 0.01, ####P < 0.001.”

**Data availability**

Other data that support the findings of this study are available from the corresponding author upon reasonable request.

**References**

1. Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394:1467–80.
2. McQuade RM, Stojanovska V, Bornstein JC, Nurgali K. Colorectal cancer chemotherapy: the evolution of treatment and new approaches. Curr Med Chem. 2017;24:1537–57.
3. Feng M, Zhao Z, Yang M, Ji J, Zhu D. T-cell-based immunotherapy in colorectal cancer. Cancer Lett. 2021;498:201–9.
4. Yang Y, Kliosky DJ. Autophagy and disease: unanswered questions. Cell Death Differ. 2020;27:858–71.
5. Kliosky DJ, Petroni G, Amaravadi RK, Baehrke EC, Ballabio A, Boya P, et al. Autophagy in major human diseases. EMBO J. 2021;40:e108863.
6. Kuwahara Y, Okawa T, Ochiai Y, Roudkani MH, Fukushima M, Shimura T, et al. Enhancement of autophagy is a potential modality for tumors refractory to radiotherapy. Cell Death Dis. 2011;2:e177.
7. Luo B, Lee AS. The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene. 2013;32:805–18.
8. Kellokkumpu S, Suokas M, Risteli L, Myllyla R. Protein disulfide isomerase and newly synthesized procollagen chains form higher-order structures in the lumen of the endoplasmic reticulum. J Biol Chem. 1997;272:2770–7.
9. Behrends C, Sowa ME, Gygi SP, Harper JW. Network organization of the human autophagy system. Nature. 2010;466:68–76.
10. Zong J, Guo C, Liu S, Sun MZ, Tang J. Proteomic research progress in lymphatic metastases of cancers. Clin Transl Oncol. 2012;14:21–30.
11. Xie L, Li H, Zhang L, Ma X, Dang Y, Guo J, et al. Autophagy-related gene P4Hβ: a novel diagnosis and prognosis marker for kidney renal clear cell carcinoma. Aging. 2020;12:1828–42.
12. Dumartin L, Alrawashdeh W, Trabulo SM, Radon TP, Steiger K, Feakins RM, et al. Caspase activity assays
13. Bai Y, Liu X, Qi X, Liu X, Peng F, Li H, et al. PDA6 modulates apoptosis and autophagy of non-small cell lung cancer cells via the MAPK4/JNK signaling pathway. ElBioMedicine. 2019;4:211–25.
14. Haspeki M, Grabowski D, Guan Y, Alugubelli RR, Triwari AD, Gu X, et al. Therapeutic targeting of protein disulfide isomerase PDI1 in multiple myeloma. Cancers (Basel). 2021;13:2649.
15. Lee E, Lee DH. Emerging roles of protein disulfide isomerase in cancer. Curr Biol. 2017;50:401–10.
16. Xiong B, Jha V, Min JK, Cho J. Protein disulfide isomerase in cardiovascular disease. Exp Mol Med. 2020;52:390–9.
17. Duncan RM, Reyes L, Moats K, Robinson RM, Murphy SA, Kaur B, et al. ATF3 coordinates antitumor synergy between epigenetic drugs and protein disulfide isomerase inhibitors. Cancer Res. 2020;80:3279–91.
18. Xu S, Butkevich AN, Yamada R, Zhou Y, Debrah B, Duncan R, et al. Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. Proc Natl Acad Sci USA. 2012;109:16348–53.
19. Kyani A, Tamura S, Yang S, Shergalis A, Samanta S, Kuang Y, et al. Discovery and mechanistic elucidation of a class of protein disulfide isomerase inhibitors for the treatment of glioblastoma. ChemMedChem. 2018;13:64–77.
20. Goplen D, Wang J, Enger PO, Tysnes BB, Terzis AJ, Laerum OD, et al. Protein disulfide isomerase inhibitors. Cancer Res. 2020;80:3279–91.
21. Goplen D, Wang J, Enger PO, Tynes BB, Terzis AJ, Laerum OD, et al. Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res. 2006;66:9895–902.
22. Xu S, Liu Y, Yang K, Wang H, Shergalis A, Kyani A, et al. Inhibition of protein disulfide isomerase in glioblastoma causes marked downregulation of DNA repair and DNA damage response genes. Theranostics. 2019;9:2282–98.
23. Tufo G, Jones AW, Wang Z, Hamelin J, Tjedjidine N, Esportit DD, et al. The protein disulfide isomerase PDIA4 and PDIA6 mediate resistance to cisplatin-induced cell death in lung adenocarcinoma. Cell Death Differ. 2014;21:685–95.
24. Liu Y, Ji W, Shergalis A, Xu J, Delaney AM, Calcaterra A, et al. Activation of the unfolded protein response via inhibition of protein disulfide isomerase decreases the capacity for DNA repair to sensitize glioblastoma to radiotherapy. Cancer Res. 2019;79:2923–32.
25. Corazzari M, Rapino F, Ciccosanti F, Giglio P, Antonioli M, Conti B, et al. Oncogenic BRAF induces chronic ER stress condition resulting in increased basal autophagy and apoptotic resistance of cutaneous melanoma. Cell Death Differ. 2015;22:946–59.
26. Lehtonen S, Jaronen M, Vehvilainen P, Lakso M, Rudalgylve M, Keksal-Goldstein V, et al. Inhibition of excessive oxidative protein folding is protective in MPP(+) toxicity-induced Parkinson’s disease models. Antioxid Redox Signal. 2016;25:485–97.
27. Won J-K, Yu SJ, Hwang CY, Cho S-H, Park S-M, Kim K, et al. Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. Hepatology. 2017;66:855–68.
27. Eirich J, Braig S, Schyschka L, Servatius P, Hoffmann J, Hecht S, et al. A small molecule inhibits protein disulfide isomerase and triggers the chemosensitivity of cancer cells. Angew Chem Int Ed 2014;53:12960–5.

28. Wang Q-W, Liu H-J, Zhao Z, Zhang Y, Wang Z, Jiang T, et al. Prognostic correlation of autophagy-related gene expression-based risk signature in patients with glioblastoma. Oncotargets Ther. 2020;13:95–107.

29. Bakker EY, Fujii M, Krstic-Demonacos M, Demonacos C, Alhammad R. Protein disulfide isomerase A1-associated pathways in the development of stratified breast cancer therapies. Int J Oncol. 2022;60:616.

30. Zhang Y, Li T, Zhang L, Shangguan F, Shi G, Wu X, et al. Targeting the functional interplay between endoplasmic reticulum oxidoreductin-1alpha and protein disulfide isomerase suppresses the progression of cervical cancer. EBioMedicine. 2019;41:408–19.

31. Zhang D, Richardson DR. Endoplasmic reticulum protein 29 (ERp29): an emerging role in cancer. Int J Biochem Cell Biol. 2011;43:33–6.

32. Zhao G, Lu H, Li C. Proapoptotic activities of protein disulfide isomerase (PDI) and PDA3 protein, a role of the Bcl-2 protein. Bak. J Biol Chem. 2015;290:8949–63.

33. Tiemann K, Gari C, Lee SB, Malhi PD, Park M, Alvarez RM, et al. Loss of ER retention motif of AGR2 can impact mTORC signaling and promote cancer metastasis. Oncogene. 2019;38:3003–18.

34. Mulcahy Levy JM, Thorburn A. Autophagy in cancer: moving from understanding mechanism to improving therapy responses in patients. Cell Death Differ. 2020;27:843–57.

35. Sasaki M, Yoshimura-Miyakoshi M, Sato Y, Nakanuma Y. A possible involvement of endoplasmic reticulum stress in biliary epithelial autophagy and senescence in primary biliary cirrhosis. J Gastroenterol. 2015;50:984–95.

36. Li N, Zoubeidi A, Beraldi E, Gleave ME. GRP78 regulates clusterin stability, retinotranslocation and mitochondrial localization under ER stress in prostate cancer. Oncogene. 2013;32:1933–42.

37. van de Rijn M, Guo X, Sweeney RT, Beck AH, West RB. Molecular pathological analysis of sarcomas using paraffin-embedded tissue: current limitations and future possibilities. Histopathology. 2014;64:183–70.

38. Li N, Zoubeidi A, Berdahl E, Gleave ME. GRP78 regulates claudin5 stability, retinotranslocation and mitochondrial localization under ER stress in prostate cancer. Oncogene. 2013;32:1933–42.

39. Ojha R, Leli NM, Onorati A, Piao S, Verginadis II, Tameire F. et al. ER translocation of the MAPK pathway drives therapy resistance in BRAF-mutant melanoma. Cancer Discov. 2019;9:396–415.

40. Asati V, Mahapatra DK, Bharti SK. Pi3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives. Eur J Med Chem. 2016;109:314–41.

41. Moujalled DM, Cook WD, Lluis JM, Khan NR, Ahmed AU, Callus BA, et al. In mouse broblasts, neither caspase-8 nor cellular FLICE-inhibitory protein (c-FLIP) is regulated by the IRE1α-mediated unfolded protein response (UPR). J Biol Chem. 2013;288:15646–53.

42. Lee AS. The ER chaperone and signaling regulator GRP78/BiP as a monitor of cancer therapy. Cancer Cell. 2015;28:224–36.

43. Mizushima N, Levine B. Autophagy in human diseases. N Engl J Med. 2004;350:1375–85.

44. Wei Y, Chiang WC, Sumpter R Jr, Mishra P, Levine B. Prohibitin 2 is an inner mitochondrial membrane mitophagy receptor. Cell. 2017;168:224–38.e10.

45. Lahiri V, Klionsky DJ. PHB2/prohibitin 2: an inner membrane mitophagy receptor. Autophagy. 2019;15:1850–5.

46. Zoubeidi A, Beraldi E, Gleave ME. GRP78 regulates clusterin stability, retinotranslocation and mitochondrial localization under ER stress in prostate cancer. Oncogene. 2013;32:1933–42.

47. van de Rijn M, Guo X, Sweeney RT, Beck AH, West RB. Molecular pathological analysis of sarcomas using paraffin-embedded tissue: current limitations and future possibilities. Histopathology. 2014;64:183–70.

48. Asati V, Mahapatra DK, Bharti SK. Pi3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives. Eur J Med Chem. 2016;109:314–41.

49. Dejirmenci U, Wang M, Hu J. Targeting aberrant RAS/RAF/MEK/ERK signaling for cancer therapy. Cells. 2020;9:198.

50. Kranz P, Neumann F, Wolf A, Classen F, Pompisch M, Ocklenburg T, et al. PDI is an essential redox-sensitive activator of PERK during the unfolded protein response (UPR). Cell Death Dis. 2017;8:e2986.

51. Lahiri V, Klionsky DJ. PHB2/prohibitin 2: an inner membrane mitophagy receptor. Cell. 2017;27:311–2.

52. Chen B, Xu F, Gao Y, Hu G, Zhu K, Lu H, et al. DNA damage-induced translocation of mitochondrial factor HIG1DA into the nucleus regulates homologous recombinaton and radio/chemo-sensitivity. Oncogene. 2022;41:1918–30.

53. Gao Y, Wen P, Chen B, Hu G, Wu L, Xu A, et al. Downregulation of CDC20 increases radiosensitivity through Mcl-1/p-Chk1-mediated DNA damage and apoptosis in tumor cells. Int J Mol Sci. 2020;21:6692.

ACKNOWLEDGEMENTS
This work was supported by the National Natural Science Foundation of China (31870845, 12122510, 32171240, and 11835014), Anhui Provincial Key R&D Program(202104a07020006), and the HFIPS Director’s Fund (BJPY2012B07 and YZJJZX202014).

AUTHOR CONTRIBUTIONS
GZ, BC, and RW designed and conceived of the study. RW, BC, YS, FX, JZ, ZZ, and XZ conducted experiments. RW, BC, GZ, YW, AX, and LW analyzed and interpreted the data. GZ and RW wrote the manuscript. All authors read and approved the final manuscript.

COMPETING INTERESTS
The authors declare no competing interests.

ETHICAL APPROVAL
The study is approved by the Ethics Committee of the Sixth Affiliated Hospital, Sun Yat-sen University (E2022083).

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41419-022-05302-w.

Correspondence and requests for materials should be addressed to Guoping Zhao. 

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2022